Fresh off a 9% quarterly sales hike, Lilly sees new launches driving solid growth through 2020

Eli Lilly isn’t expecting an easy drug pricing environment going forward. But never fear, investors: It’s expecting volume gains.

Tuesday, the Indianapolis pharma giant predicted 5% revenue growth per year through the end of the decade--welcome news for a company that’s struggled to pick itself back up after patent expirations hit.

And that volume growth is already coming. For the second quarter, the company posted 10% volume expansion in its pharmaceutical unit, which took revenue up 9% year over year to reach $5.40 billion. Reported EPS rocketed upward, too, rising to 71 cents from 56 cents--a 27% increase.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Lilly, which suffered through a number of development setbacks in recent years before recently seeing some new products hit, has its new launches to thank for the Q2 performance. Cancer-fighter Cyramza leapt 79% to reach $278 million in worldwide sales, making up for a 4% U.S. slide from increased competition in non-small-cell lung cancer.

And a trio of diabetes meds came up big, too. Trulicity, the company’s GLP-1 contender, hauled in $201.3 million amid an increase in market share. SGLT2 standout Jardiance--which last year became the first diabetes therapy to show it could cut the combined risk of heart attack, stroke and cardiovascular death--netted $40.1 million. Brand-new Basaglar, the biosimilar version of Sanofi's megablockbuster Lantus, showed some early uptake success with a $16.3 million tally.

Lilly also highlighted Taltz, a next-gen psoriasis med that’s generated $19.3 million since its U.S. launch in April.

The way Lilly sees it, the company couldn’t be hitting its stride at a better time. As CEO John Lechleiter told CNBC Tuesday morning, he sees a future where drug pricing will be challenging across the board, meaning drugmakers won’t be able to rely on the price hikes they’ve so often employed in the past. Lilly has been among them: Between 2007 and 2014, the pharma took the list price of diabetes blockbuster Humulin up 354%.

Shareholders have nothing to worry about now, though, diabetes VP Mike Mason said on last quarter’s conference call. The company isn’t worried about net price concerns for its newer products, which should carry the company’s top line going forward.

- read Lilly's release

Special Report: 10 big brands keep pumping out big bucks, with a little help from price hikes

Related Articles:
Lilly fortifies its Trulicity case with new Lantus-beating combo data
Lilly execs: Net price pressures not a concern for new diabetes meds
Reduce CV events, check. Now, Lilly, BI's Jardiance shows it can cut kidney disease risk, too
Can Lilly hotshot Jardiance steam ahead if SGLT2s slow down?
Lilly's new psoriasis med faces off against Novartis'
Riding Q4 diabetes growth, Lilly aims for even more with Jardiance
You say you want a revolution? Lilly, BI and Jardiance may trigger one in diabetes
Lilly's blockbuster hopeful Cyramza nabs key new use in lung cancer


Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.